About Kancera AB (publ)
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market.
The case
- Leaders in drug development of small molecule fractalkine blockers: Kancera is developing two drug candidates with the same mode of action; the CX3CR1 antagonists KAND567 and KAND145.
- R&D achievements verifying business strategy: Two drug candidates (KAND567 and KAND145) delivered from preclinical stage to clinical development in human.
- Maturing pipeline:
- FRACTAL-study: Aiming to prevent reperfusion injury and cardiovascular death caused by excessive inflammation in STEMI patients undergoing PCI: Phase IIa study completed, positive top line results reported in December 2023.
- KANDOVA-study: Aiming to increase efficacy of platinum-therapy in ovarian cancer with relapse: Ongoing combined phase Ib/IIa study conducted at several university hospitals in Sweden, Norway and Denmark with targeted top line results before end of 2024.
- KAND145: 2nd generation fractalkine blocker intended for cancer indications. Ongoing first in human phase I study at two sites in Finland with expected top line results in Q2 2024.
- Kancera’s business model is to conduct late-stage development and commercialization in partnership with pharmaceutical companies focusing on specialty care and Kancera is now intensifying its business development activities.